

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### Evaluation of the effects of ginger consumption on eradication of H.pylori, clinical symptoms, inflammatory factors, and oxidative stress in patients with peptic ulcer

#### Protocol summary

##### Study aim

To determine the effects of ginger consumption on eradication of H.pylori, clinical symptoms, inflammatory factors, and oxidative stress in patients with peptic ulcer

##### Design

A randomized, double-blinded, controlled clinical trial with a parallel group design of 42 patients. Random number table will be used for randomization.

##### Settings and conduct

42 eligible patients with peptic ulcer will randomly assign to consume four tablets daily each containing 500 mg of ginger or placebo for six weeks. Both groups will also receive the standard medical treatment in hospital. Patients' blood samples will be taken before and after the intervention to determine inflammation factors and oxidative stress markers and the two groups will also be compared in eradication of H.pylori and clinical signs. In this study participants and investigators will be blinded and concealment will be done by a third person.

##### Participants/Inclusion and exclusion criteria

People with a diagnosis of peptic ulcer and in the age range of 18-80 who are able to intake tablets orally and desire to participate in the study will be included in the study. While people having pregnancy or breastfeeding, any history of allergy to ginger, antibiotic use in the last 4 weeks, active alcohol consumption or alcohol, corticosteroid and anticoagulant use, Cardiovascular, liver, lung, kidney diseases, malignancy, recent surgery will be excluded from the study.

##### Intervention groups

1- intervention groups: receiving 2g of ginger daily in the form of 500mg tablets for 6 weeks; 2-Placebo group: placebo tablets for 6 weeks

##### Main outcome variables

Eradication of H.pylori; serum IL-8 level, serum TAC level; degree of heartburn and stomach pain; length of indigestion; score of dyspepsia questionnaire

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20100524004010N35**

Registration date: **2023-02-08, 1401/11/19**

Registration timing: **registered\_while\_recruiting**

Last update: **2023-02-08, 1401/11/19**

Update count: **0**

##### Registration date

2023-02-08, 1401/11/19

##### Registrant information

##### Name

Azita Hekmatdoost

##### Name of organization / entity

Shahid Beheshti University of Medical Sciences,  
National Institute of Nutrition Research

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 2293 0824

##### Email address

hekmat@sina.tums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-02-08, 1401/11/19

##### Expected recruitment end date

2023-05-09, 1402/02/19

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of the effects of ginger consumption on eradication of H.pylori, clinical symptoms, inflammatory factors, and oxidative stress in patients with peptic ulcer

**Public title**

Evaluation of the effects of ginger consumption on eradication of H.pylori, clinical symptoms, inflammatory factors, and oxidative stress in patients with peptic ulcer

**Purpose**

Supportive

**Inclusion/Exclusion criteria****Inclusion criteria:**

General desire to practice the study Age over 18 years and less than 80 years Confirmation of H. pylori infection by stool antigen test or endoscopic pathology findings No antibiotic use in the last 4 weeks No active alcohol consumption or alcohol, corticosteroid and anticoagulant use No diseases Cardiovascular, liver, lung, kidney, malignancy Absence of recent surgery Absence of pregnancy or breastfeeding in women Absence of allergy to H pylori infection eradication regimen

**Exclusion criteria:**

Unwilling to continue the study Any allergic reaction to the supplements Consumption of less than 90% of supplements at the end of the study period

**Age**

From **18 years** old to **80 years** old

**Gender**

Both

**Phase**

2

**Groups that have been masked**

- Participant
- Investigator

**Sample size**

Target sample size: **42**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Patients will be randomized into ginger group or placebo according to the table of random numbers at the beginning of the study.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

Patients won't know if they are receiving the ginger or a placebo tablets and for double-blinding the study, the bottles containing the relevant tablets will be concealed as A and B by a third person at the beginning of the study, and none of the research team members will know the type of tablets received by each group.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committie of the National Institute of Research and Food Industry

**Street address**

NO.7,West Arghavan Ave.,Farahzadi Blvd.,Qods Town

**City**

Tehran

**Province**

Tehran

**Postal code**

1981619573

**Approval date**

2023-01-21, 1401/11/01

**Ethics committee reference number**

IR.SBMU.NNFTRI.REC.1401.057

**Health conditions studied****1****Description of health condition studied**

Peptic ulcer

**ICD-10 code**

K27

**ICD-10 code description**

Peptic ulcer, site unspecified

**Primary outcomes****1****Description**

H.Pylori eradication

**Timepoint**

8 week

**Method of measurement**

Endoscopy and Pathology

**2****Description**

Clinical Symptoms

**Timepoint**

8 week

**Method of measurement**

Questionnaire

**3****Description**

Anti-oxidant status

**Timepoint**

8 week

**Method of measurement**

ELISA

**Secondary outcomes**

empty

**Intervention groups****1****Description**

Intervention group: will take 2g of ginger daily in the form of four tablets each contains 500 mg of ginger (Product of Dine Company) orally for six weeks.

**Category**

Other

**2****Description**

Control group: will take four placebo tablets daily, which are similar in shape and taste to ginger tablet, orally for 6 weeks

**Category**

Placebo

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Taleghani General Hospital

**Full name of responsible person**

Amir Sadeghi

**Street address**

Ayatollah Taleghani Educational Hospital, Araabi St. Yaman Ave, Chamran High Way, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1985711151

**Phone**

+98 21 2243 2560

**Email**

taleghanihospital@sbmu.ac.ir

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Azita Hekmatdoost

**Street address**

No.7, West Arghavan Ave., Farahzad Blvd., Qods Town

**City**

Tehran

**Province**

Tehran

**Postal code**

1981619573

**Phone**

+98 21 2235 7483

**Email**

a\_hekmat2000@yahoo.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shahid Beheshti University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Azita Hekmatdoost

**Position**

Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

No. 7, West Arghavan Ave., Farahzadi Blvd., Qods Town

**City**

Tehran

**Province**

Tehran

**Postal code**

1981619573

**Phone**

+98 21 2235 7483

**Fax****Email**

a\_hekmat2000@yahoo.com

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Azita Hekmatdoost

**Position**

Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

No. 7, West Arghavan Ave., Farahzadi Blvd., Qods Town

**City**

Tehran

**Province**

Tehran

**Postal code**

1981619573

**Phone**

+98 21 2235 7483

**Email**

a\_hekmat2000@yahoo.com

No. 7, West Arghavan Ave., Farahzadi Blvd., Qods Town

**City**

Tehran

**Province**

Tehran

**Postal code**

1981619573

**Phone**

+98 21 2235 7483

**Email**

a\_hekmat2000@yahoo.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

**Person responsible for updating data****Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Azita Hekmatdoost

**Position**

Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**